References
1. Morgan CL, Jenkins-Jones S, Currie CJ, Rees DA. Evaluation of adverse outcome in young women with polycystic ovary syndrome versus matched, reference controls: a retrospective, observational study. J Clin Endocrinol Metab 2012;97:3251-3260.
2. González F. Inflammation in Polycystic Ovary Syndrome: underpinning of insulin resistance and ovarian dysfunction. Steroids 2012;77:300-305
3. Ohsawa I, Inoshita H, Ishii M, Kusaba G, Sato N, Mano S, et al. Metabolic impact on serum levels of complement component 3 in Japanese patients. J Clin Lab Anal 2010;24:113-118
4. Engström G, Hedblad B, Eriksson KF, Janzon L, Lindgärde F. Complement C3 is a risk factor for the development of diabetes: a population-based cohort study. Diabetes 2005;54:570-575
5. Engström G, Hedblad B, Janzon L, Lindgärde F. Complement C3 and C4 in plasma and incidence of myocardial infarction and stroke: a population-based cohort study. Eur J Cardiovasc Prev Rehabil 2007;14:392-397
6. Maslowska M, Sniderman A, Germinario R, Cianflone K. ASP stimulates glucose transport in cultured human adipocytes. Int J Obes Relat Metab Disord 1997;21:261-266
7. Cianflone K, Roncari DA, Maslowska M, Baldo A, Forden J, Sniderman AD. Adipsin/acylation stimulating protein system in human adipocytes: regulation of triacylglycerol synthesis. Biochemistry 1994;33:9489-9495
8. Faraj M, Sniderman A, Cianflone K. ASP enhances in situ lipoprotein lipase activity by increasing fatty acid trapping in adipocytes. J Lipid Res 2004;45:657-666
9. Tao Y, Cianflone K, Sniderman A, Colby-Germinario S, Germinario R. Acylation-stimulating protein (ASP) regulates glucose transport in the rat L6 muscle cell line. Biochim Biophys Acta 1997;1344:221-229
10. Maslowska M, Scantlebury T, Germinario R, Cianflone K. Acute in vitro production of acylation stimulating protein in differentiated human adipocytes. J Lipid Res 1997;38:1-11
11. Fujita T, Fujioka T, Murakami T, Satomura A, Fuke Y, Matsumoto K. Chylomicron accelerates C3 tick-over by regulating the role of factor H, leading to overproduction of acylation stimulating protein. J Clin Lab Anal 2007;21:14-23
12. Peake PW, Kriketos AD, Campbell LV, Charlesworth JA. Response of the alternative complement pathway to an oral fat load in first-degree relatives of subjects with type II diabetes. Int J Obes (Lond) 2005;29:429-435
13. van Oostrom AJ, Alipour A, Plokker TW, Sniderman AD, Cabezas MC. The metabolic syndrome in relation to complement component 3 and postprandial lipemia in patients from an outpatient lipid clinic and healthy volunteers. Atherosclerosis 2007;190:167-173
14. Meijssen S, van Dijk H, Verseyden C, Erkelens DW, Cabezas MC. Delayed and exaggerated postprandial complement component 3 response in familial combined hyperlipidemia. Arterioscler Thromb Vasc Biol 2002;22:811-816
15. Halkes CJ, van Dijk H, de Jaegere PP, Plokker HW, van Der Helm Y, Erkelens DW, et al. Postprandial increase of complement component 3 in normolipidemic patients with coronary artery disease: effects of expanded-dose simvastatin. Arterioscler Thromb Vasc Biol 2001;21:1526-1530
16. Gursoy Calan O, Calan M, Yesil Senses P, Unal Kocabas G, Ozden E, Sari KR, et al. Increased adipsin is associated with carotid intima media thickness and metabolic disturbances in polycystic ovary syndrome. Clin Endocrinol 2016;85:910-917.
17. Wu Y, Zhang J, Wen Y, Wang H, Zhang M, Cianflone K. Increased acylation-stimulating protein, C-reactive protein, and lipid levels in young women with polycystic ovary syndrome. Fertil Steril 2009;91:213-219
18. Oktenli C, Ozgurtas T, Dede M, Sanisoglu YS, Yenen MC, Yesilova Z, et al. Metformin decreases circulating acylation-stimulating protein levels in polycystic ovary syndrome. Gynecol Endocrinol 2007;23:710-5.
19. Yang S, Li Q, Song Y, Tian B, Cheng Q, Qing H, et al. Serum complement C3 has a stronger association with insulin resistance than high-sensitivity C-reactive protein in women with polycystic ovary syndrome. Fertil Steril 2011;95:1749-1753
20. Dehdashtihaghighat S, Mehdizadehkashi A, Arbabi A, Pishgahroudsari M, Chaichian S. Assessment of C-reactive protein and C3 as inflammatory markers of insulin resistance in women with polycystic ovary syndrome: a case-control study. J Reprod Infertil 2013;14:197-201.
21. Snyder ML, Shields KJ, Korytkowski MT, Sutton-Tyrrell K, Talbott EO. Complement protein C3 and coronary artery calcium in middle-aged women with polycystic ovary syndrome and controls. Gynecol Endocrinol 2014;30:511-515.
22. Rees E, Coulson R, Dunstan F, Evans WD, Blundell HL, Luzio SD, et al. Central arterial stiffness and diastolic dysfunction are associated with insulin resistance and abdominal obesity in young women but polycystic ovary syndrome does not confer additional risk. Hum Reprod 2014;29:2041-2049
23. Watson S, Blundell HL, Evans WD, Griffiths H, Newcombe RG, Rees DA. Can abdominal bioelectrical impedance refine the determination of visceral fat from waist circumference? Physiol Meas 2009;30:N53-58
24. Giles JL, Choy E, van den Berg C, Morgan BP, Harris CL. Functional analysis of a complement polymorphism (rs17611) associated with rheumatoid arthritis. J Immunol 2015;194:3029-3034
25. Ingram G, Hakobyan S, Hirst CL, Harris CL, Loveless S, Mitchell JP, et al. Systemic complement profiling in multiple sclerosis as a biomarker of disease state. Mult Scler 2012;18:1401-1411
26. Hakobyan S, Harris CL, Tortajada A, Goicochea de Jorge E, García-Layana A, Fernández-Robredo P, et al. Measurement of factor H variants in plasma using variant-specific monoclonal antibodies: application to assessing risk of age-related macular degeneration. Invest Ophthalmol Vis Sci 2008;49:1983-1990
27. Cianflone K, Xia Z, Chen LY. Critical review of acylation-stimulating protein physiology in humans and rodents. Biochem Biophys Acta 2003;1609:127-143.
28. Maslowska M, Vu H, Phelis S, Sniderman AD, Rhode BM, Blank D, et al. Plasma acylation stimulating protein, adipsin and lipids in non-obese and obese populations. Eur J Clin Invest 1999;29:679-686.
29. Koistinen HA, Vidal H, Karonen SL, Dusserre E, Vallier P, Koivisto VA, et al. Plasma acylation stimulating protein concentration and subcutaneous adipose tissue C3 mRNA expression in nondiabetic and type 2 diabetic men. Arterioscler Thromb Vasc Biol 2001;21:1034-1039.
30. Xin Y, Hertle E, van der Kallen CJH, Schalkwijk CG, Stehouwer CDA, van Greevenbroek MMJ. Longitudinal associations of the alternative and terminal pathways of complement activation with adiposity: The CODAM study. Obes Res Clin Pract 2018;12:286-292.
31. Engstrom G, Hedblad B, Janzon L, Lindgarde F. Weight gain in relation to plasma levels of complement factor 3: results from a population-based cohort study. Diabetologia 2005;48:2525-2531.
32. Xin Y, Hertle E, van der Kallen CJH, Schalwijk CG, Stehouwer CDA, van Greevenbroek MMJ. Complement C3 and C4, but not their regulators or activated products, are associated with incident metabolic syndrome: the CODAM study. Endocrine 2018;62:617-627.
33. Daan NM, Koster MP, de Wilde MA, Dalmeijer GW, Evelein AM, Fauser BC, et al. Biomarker profiles in women with PCOS and PCOS offspring: a pilot study. PLoS One 2016;11(11):e0165033
34. Sivakumar K, Bari MF, Adaikalakoteswari A, Guller S, Weickert MO, Randeva HS, et al. Elevated fetal adipsin/acylation-stimulating protein (ASP) in obese pregnancy: novel placental secretion via hofbauer cells. J Clin Endocrinol Metab 2013;98:4113-4122.
35. Matsunaga H, Iwashita M, Shinjo T, Yamashita A, Tsuruta M, Nagasaka S, et al. Adipose tissue complement factor B promotes adipocyte maturation. Biochem Biophys Res Commun 2018;495:740-748.
36. Moreno-Navarette JM, Martinez-Barricarte R, Catalan V, Sabater M, Gomez-Ambrosi J, Ortega FJ, et al. Complement factor H is expressed in adipose tissue in association with insulin resistance. Diabetes 2010;59:200-209.
37. Harboe M, Ulvund G, Vien L, Fung M, Mollnes TE. The quantitative role of alternative pathway amplification in classical pathway induced terminal complement activation. Clin Exp Immunol 2004;138:439-446.
38. Harboe M, Garred P, Karlstrøm E, Lindstad JK, Stahl GL, Mollnes TE. The down-stream effects of mannan-induced lectin complement pathway activation depend quantitatively on alternative pathway amplification. Mol Immunol 2009;47:373-380.
39. Bansal S, Buring JE, Rifai N, Mora S, Sacks FM, Ridker PM. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. J Am Med Assoc 2007;298:309-315.
40. Vaisar T, Pennathur S, Green P, Gharib S, Hoofnagle A, Cheung M, et al. Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. J Clin Invest 2007;117:746-756.
41. Haapasalo K, van Kessel K, Nissilä E, Metso J, Johansson T, Miettinen S, et al. Complement factor H is expressed in adipose tissue in association with insulin resistance. Diabetes 2010;59:200-209.
42. Martínez A, Pío R, López J, Cuttitta F. Expression of the adrenomedullin binding protein, complement factor H, in the pancreas and its physiological impact on insulin secretion. J Endocrinol 2001;170:503-511.
43. Charlesworth JA, Peake PW, Campbell LV, Pussell BA, O’Grady S, Tzilopoulos T. The influence of oral lipid loads on acylation stimulating protein in healthy volunteers. Int J Obes Relat Metab Disord 1998;22:1096-1102.
44. Peake PW, Kriketos AD, Campbell LV, Charlesworth JA. Response of the alternative complement pathway to an oral fat load in first-degree relatives of subjects with type II diabetes. Int J Obes 2005;29:429-435.
45. Kalant D, Phélis S, Fielding BA, Frayn KN, Cianflone K, Sniderman AD. Increased postprandial fatty acid trapping in subcutaneous adipose tissue in obese women. J Lipid Res 2000;41:1963-1968
46. Saleh J, Summers L, Cianflone K, Fielding B, Sniderman A, Frayn K. Coordinated release of acylation stimulating protein (ASP) and triacylglycerol clearance by human adipose tissue in vivo in the postprandial period. J Lipid Res 1998;39:884-891.
47. Gabrielsson B, Johansson J, Lönn M, Jernås M, Olbers T, Peltonen M, et al. High expression of complement components in omental adipose tissue in obese men. Obes Res 2003;11:699-708
48. Munkonda MN, Martin J, Poirier P, Carrington A, Biron S, Lebel S, et al. Acylation stimulating protein reduction precedes insulin sensitization after BPD-DS bariatric surgery in severely obese women. Nutr Diabetes 2012; 2:e41. doi: 10.1038/nutd.2012.13.
49. Schrauwen P, Hesselink MK, Jain M, Cianflone K. Acylation-stimulating protein: effect of acute exercise and endurance training. Int J Obes 2005;29:632-638.
50. Ricklin D, Lambris JD. Therapeutic control of complement activation at the level of the central component C3. Immunobiology 2016;221:740-746.